New Indications for Cyramza
November 5, 2014 – Cyramza® (ramucirumab — Lilly), originally FDA-approved in April 2014 as monotherapy to treat patients with certain stomach cancers, is used as second-line therapy for advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma that have progressed despite or during chemotherapy with a platinum-based or fluoropyrimidine drug. In early November, Cyramza received new indications for the same conditions, but in combination with paclitaxel, also a cancer drug.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Prices referenced are estimates based on available data and are subject to change at the time a claim is processed. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information purposes only. The reference to any medication above does not imply that the medication is covered by your plan.